Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans | RxWiki

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

Overview[ - collapse ][ - ]

Purpose	The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.
Condition	Healthy Type 2 Diabetes Mellitus
Intervention	Drug: Metformin
Phase	Phase 4
Sponsor	University of California, San Francisco
Responsible Party	University of California, San Francisco
ClinicalTrials.gov Identifier	NCT01681693
First Received	August 1, 2012
Last Updated	September 24, 2013
Last verified	September 2013

Tracking Information[ + expand ][ + ]

First Received Date	August 1, 2012
Last Updated Date	September 24, 2013
Start Date	February 2010
Estimated Primary Completion Date	July 2013
Current Primary Outcome Measures	Renal Clearance of the Metformin [Time Frame: 24 hours post-dose] [Designated as safety issue: No]To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered pharmacokinetics of metformin. Plasma glucose [Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes after glucose administration] [Designated as safety issue: No]To test whether individuals with genetic variants of transporters OCT3 and MATE1 exhibit altered glucose lowering response to metformin.
Current Secondary Outcome Measures	Not Provided

Descriptive Information[ + expand ][ + ]

Brief Title	Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans
Official Title	Effect of Genetic Variants in MATE1 and OCT3 Transporters on the Pharmacodynamics of Metformin in African Americans With Type II Diabetes Mellitus.
Brief Summary	The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.
Detailed Description	To investigate the potential association of polymorphic genetic variants MATE1 and OCT3 with altered response to metformin, a genotype to phenotype strategy is employed. Specifically, the investigators will evaluate this hypothesis in African-Americans, a population which has a high incidence of type 2 diabetes and which has high variant allele frequencies (44.5% for MATE1-66T>C and 11.3% in OCT3-81G>delGA) relative to other ethic groups. To assess the effects of these variants on metformin response, the investigators will measure metformin renal clearance (pharmacokinetics of metformin), and plasma glucose and insulin levels (pharmacodynamic response) in healthy and diabetic patients who carry either the reference or variant alleles.
Study Type	Interventional
Study Phase	Phase 4
Study Design	Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Condition	Healthy Type 2 Diabetes Mellitus
Intervention	Drug: Metformin Subjects will be given an oral dose of metformin once per day for two days. Other Names: GLUCOPHAGE
Study Arm (s)	Experimental: Metformin Subjects will be given an oral dose of metformin once per day for two days.

Recruitment Information[ + expand ][ + ]

Recruitment Status	Completed
Estimated Enrollment	33
Estimated Completion Date	July 2013
Estimated Primary Completion Date	July 2013
Eligibility Criteria	Inclusion Criteria: - Subjects self-identify racial background, identify themselves, parents and four grandparents as African American - Subject status is healthy volunteer from t In the event that diabetes is indicated in a normal subject based on OGTT results, we will notify the patients' primary care physician. he SOPHIE cohort OR diagnosis of T2DM based on American Diabetes Association (ADA) criteria - Subjects over 18 years old and below 60 years - Subjects who are healthy on the basis of medical history, physical examinations and laboratory tests if healthy volunteer from SOPHIE - Subjects who agree with the written informed consent to participate in the study Exclusion Criteria: - Unable to confirm African-American ethnicity - Under 18 years old - Pregnant or lactating women (female subjects will have a urine pregnancy test at the screening visit). - Prior history of any allergic reaction to metformin - Has a risk of congestive heart failure requiring pharmacologic treatment (medical history) - Has a prior history of renal* or hepatic dysfunction (renal and hepatic function will be evaluated based on screening blood tests conducted prior to study enrollment) - Risk of urinary or gastric retention or narrow-angle glaucoma (by medical history examination) - Impaired renal function (e.g as suggested by abnormal creatinine clearance, eGFR <60 or serum creatinine >1.4 mg/dl in females and >1.5 mg/dl in males) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction (heart attack), and septicemia, abnormal heart rhythms (tachyarrhythmias; heart beat > 100 beats per minute). - Impaired hepatic function (> 1.5 times the upper limit of normal) - Evidence of anemia (hemoglobin <10 g) - Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine. - They do not provide consent to participate in the study.
Gender	Both
Ages	18 Years
Accepts Healthy Volunteers	Accepts Healthy Volunteers
Contacts	Not Provided
Location Countries	United States

Administrative Information[ + expand ][ + ]

NCT Number	NCT01681693
Other Study ID Numbers	6113
Has Data Monitoring Committee	Yes
Information Provided By	University of California, San Francisco
Study Sponsor	University of California, San Francisco
Collaborators	Not Provided
Investigators	Principal Investigator: Kathleen M Giacomini, PhD University of California, San Francisco
Verification Date	September 2013

Locations[ + expand ][ + ]